(Press-News.org) Peer-reviewed / Randomised Controlled Trial / People
Peer-reviewed / Randomised Controlled Trial / People
The Lancet Infectious Diseases: Taking a common diabetes medication after testing positive for SARS-CoV-2 reduces risk of developing long COVID by 40%, study finds
US study of 1,126 overweight and obese people finds 6.3% of participants who took metformin, a medication commonly used to control blood sugar in people with type 2 diabetes, within three days of testing positive for SARS-CoV-2 reported a long COVID diagnosis within 10 months, compared to 10.4% of those who received a placebo.
This is the first published randomised control trial to suggest medication taken during the acute phase of COVID-19 may be able to reduce the risk of long COVID.
Authors caution that the trial did not look at the effect of metformin on those who already had a long COVID diagnosis so it cannot draw any conclusions about metformin as a treatment for long COVID. They suggest further trials of metformin on those with lower BMI and previous SARS-CoV-2 infection.
Taking a two-week course of metformin, a safe and affordable diabetes medication after testing positive for SARS-CoV-2 leads to 40% fewer long COVID diagnoses over the following 10 months, compared to individuals taking a placebo, finds a new study published in The Lancet Infectious Diseases journal.
The long-term symptoms some people experience after SARS-CoV-2 infection, known as long COVID, are an emerging chronic illness potentially affecting millions of people around the world. Currently there are no proven treatments or ways to prevent long COVID, other than reducing the risk of infection in the first place.
This is the first phase 3 randomised controlled trial of a treatment for patients in the community that shows a medication can reduce the risk of long COVID when taken after testing positive for SARS-CoV-2.
“Long COVID is a significant public health emergency that may have lasting physical health, mental health, and economic impacts, especially in socioeconomically marginalised groups. There is an urgent need to find potential treatments and ways to prevent this disease. Our study showed that metformin, a medication that is safe, low-cost, and widely available, substantially reduces the risk of being diagnosed with long COVID if taken when first infected with the coronavirus. This trial does not indicate whether metformin would be effective as a treatment for those who already have long COVID,” says first author Dr Carolyn Bramante, University of Minnesota Medical School, USA. [1]
Participants in the trial were not hospitalised, were at a higher risk of severe COVID-19 (overweight or obesity), over the age of 30, and had tested positive for SARS-CoV-2 within the last three days but had no known previous SARS-CoV-2 infection. Trial recruitment was open from December 2020 to January 2022 with 1,126 patients given either metformin or an identical placebo pill after testing positive for SARS-CoV-2 during that time. Participants were followed up for 10 months with data gathered by self-report questionnaire every 30 days.
Metformin prevented over 40% of cases of long COVID in the trial with 6.3% (35/564) of participants given metformin reporting a long COVID diagnosis within 10 months of follow up, compared to 10.4% (58/562) of those receiving an identical placebo.
These findings reflect previously published results from this trial which found metformin prevented over 40% of emergency department visits, hospitalisations, and deaths due to COVID within two weeks of starting the treatment, compared to a placebo [2].
Other arms of the trial looked at ivermectin and fluvoxamine and found that neither prevented long COVID.
“Previous studies have found that metformin stops the SARS-CoV-2 virus from replicating in the lab [3,4], which is consistent with predictions from our mathematical modelling of viral replication, so that might be what is causing the reduction in both severe COVID-19 and Long COVID diagnoses seen in this trial,” says co-author David Odde, University of Minnesota biomedical engineer.
The authors acknowledge some limitations to the study, including that the trial excluded those with a BMI under 25 and those younger than 30 years, and therefore it is unknown if these findings could be generalised to those populations. They also caution that when the long COVID assessment was added to the trial, little was known about the best assessment tool for long COVID occurrence in clinical trial participants, however they believe the use of a long COVID diagnosis from a medical provider, as well as the long duration of follow-up, would address some of the issues around the changing nature of this disease definition.
Writing in a Linked Comment, Dr Jeremy Faust, Harvard Medical School, USA, who was not involved in this research, said: “If confirmed, the findings from the study by Bramante and colleagues are profound and potentially landmark […] this is the first high-quality evidence from a randomised controlled trial to show that the incidence of long COVID can be reduced by a medical intervention, metformin—an inexpensive treatment with which clinicians have ample experience.”
NOTES TO EDITORS
This study was funded by Parsemus Foundation, Rainwater Charitable Foundation, Fast Grants, and the UnitedHealth Group Foundation. See the Article for a full list of author affiliations.
[1] Quote direct from author and cannot be found in the text of the Article.
[2] Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for COVID-19. The New England journal of medicine 2022; 387(7): 599-610.
[3] Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. 2022 Nov 20;323:199010.
[4] Schaller et al., JCI Insight, 2021 and Gordon et al., Nature, 2020
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext
END
THE LANCET INFECTIOUS DISEASES: Taking a common diabetes medication after testing positive for SARS-CoV-2 reduces risk of developing long COVID by 40%, study finds
2023-06-09
ELSE PRESS RELEASES FROM THIS DATE:
Confidence in vaccines has plummeted in Africa since the pandemic – Study across eight countries shows
2023-06-09
Public confidence in vaccines has plunged across sub-Saharan Africa since the COVID-19 pandemic, according to a study of 17,000 people, across eight countries, published today in the peer-reviewed journal Human Vaccines & Immunotherapeutics.
The findings come as the World Health Organization and UNICEF have reported the largest sustained fall in uptake of routine childhood immunizations in three decades.
Six million fewer children in Africa received routine shots for diseases including tetanus, polio, diphtheria and measles over the past ...
LGB adults at higher risk of suicidal thoughts and self-harm
2023-06-09
Lesbian, gay and bisexual (LGB) people are more than twice as likely than their straight peers to experience suicidal thoughts or self-harming behaviours, finds a new study led by UCL researchers.
The study, published in Social Psychiatry and Psychiatric Epidemiology, is the first ever to analyse nationally representative data on sexual orientation and suicidality in England whilst being able to compare individual sexual minority groups. The researchers analysed data combined from two household surveys of 10,443 English adults (aged 16 and over), representative of the population, sampled in 2007 and 2014.
As ...
University of Arizona launching computer science and engineering B.S.
2023-06-08
Right now, United States employers are unable to fill around 1 million computer science-related jobs because of a lack of qualified candidates, as estimated by the Bureau of Labor Statistics. And the demand isn’t going away – the bureau projects employment in the field to grow much faster than average through 2031, while the number of graduates will continue to lag behind job openings.
This workforce need is the primary reason the College of Engineering will soon offer a bachelor's degree in computer science and engineering, said Michael Wu, head of the Department of Electrical and Computer Engineering, which houses the ...
Children in Chile saw 73% fewer TV ads for unhealthy foods and drinks following trailblazing marketing restrictions
2023-06-08
Chilean policies aimed at reining in unhealthy food marketing are succeeding in protecting children from the onslaught of television advertisements (TV ads) for these products, according to new research. The country’s multi-phased regulations, which began in 2016, have led to a 73% drop in children’s exposure to TV ads for regulated foods and drinks (those that exceed legal thresholds for calories, sugar, salt or saturated fat) by 2019. During this time, the number of ads for unhealthy foods dropped 64% on all TV programs ...
Incomplete imaging for transient ischemic attack emergencies increases stroke risk
2023-06-08
Leesburg, VA, June 8, 2023—According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), transient ischemic attack (TIA) emergency department (ED) encounters with incomplete neurovascular imaging were associated with higher odds of subsequent stroke within 90 days.
“Increased access to urgent neurovascular imaging in patients with TIA may represent a target that could facilitate detection and treatment of modifiable stroke risk factors,” wrote first author Vincent M. Timpone, MD, from the department of radiology at the University of Colorado Hospital in Aurora.
Timpone et al. ...
Researchers create engineered human tissue to study mosquito bites, disease
2023-06-08
Researchers Create Engineered Human Tissue to Study Mosquito Bites, Disease
Scientists hope to use this new platform to study how pathogens that mosquitoes carry impact and infect human cells and tissues.
By Eric Eraso | June 8, 2023
A UCF research team has engineered tissue with human cells that mosquitoes love to bite and feed upon — with the goal of helping fight deadly diseases transmitted by the biting insects.
A multidisciplinary team led by College of Medicine biomedical researcher Bradley Jay Willenberg with Mollie Jewett (UCF Burnett School of Biomedical Sciences) and Andrew Dickerson (University of Tennessee) ...
Mass General Cancer Center researchers share Insights on the evolution of proton radiotherapy
2023-06-08
As one of the first hospitals in the world to establish a proton radiotherapy program to treat cancer, Massachusetts General Hospital (MGH) and the Mass General Cancer Center have been pioneers in using and improving proton therapy for treating both benign and malignant tumors effectively while delivering a lower dose of radiation to tissue surrounding the target site. Researchers at MGH have led and continue to lead studies that are defining the best use of proton therapy, which is now being offered at 106 centers worldwide.
In a Review article published in The ...
Utilizing data to predict hospital wait times – it can save more than your patience!
2023-06-08
INFORMS Journal Manufacturing & Service Operations Management New Study Key Takeaways:
Researchers develop a method to more accurately predict and showcase hospital wait times to patients and emergency personnel by using new information that is learned in the intake process.
This method provides more up-to-date wait times allowing patients and paramedics to make choices about which emergency department to go to.
This process streamlines patient flow, creates more uniform spread of patients and lowers congestion across emergency departments, and could improve patient outcomes ...
MethaneMapper is poised to solve the problem of underreported methane emissions
2023-06-08
(Santa Barbara, Calif.) — Wildfires. Many see them as purely destructive forces, disasters that blaze through a landscape, charring everything in their paths. But a study published in the journal Ecology Letters reminds us that wildfires are also generative forces, spurring biodiversity in their wakes.
“There’s a fair amount of biodiversity research on fire and plants,” said Max Moritz, a wildfire specialist with UC Cooperative Extension who is based at UC Santa Barbara’s Bren School of Environmental Science & Management, and is the study’s lead author. Research has shown that in ecosystems where fire is a natural and regular occurrence, there ...
For pet dogs, ‘running with the pack’ may be the best prevention to promote healthier living
2023-06-08
What exactly makes for a fit Fido? And how does a dog’s environment factor into their dog years?
“People love their dogs,” said ASU School of Life Sciences assistant professor Noah Snyder-Mackler. “But what people may not know, is that this love and care, combined with their relatively shorter lifespans, make our companion dogs a great model for studying how and when aspects of the social and physical environment may alter aging, health and survival.”
Now, the largest survey and data compilation of its kind--- from more than 21,000 dog owners--- has revealed the social determinants that may be ...